SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

Published on June 3, 2026
ALISO VIEJO, Calif.—SpyGlass Pharma, Inc. (Nasdaq: SGP), a late-stage biopharmaceutical company focused on transforming treatment paradigms for patients with chronic eye conditions, has announced the appointment of Mike Pinder as vice president, marketing, effective May 18, 2026. Pinder brings more than 20 years of commercial launch experience in ophthalmology, focused on building, launching and evolving brands, notably in the buy-and-bill specialty pharma model, the announcement said. In the newly created role, SpyGlass Pharma said he will build and lead the company’s marketing function as it continues to progress the Bimatoprost Drug Pad-IOL System (BIM-IOL System) through phase 3 clinical trials and toward potential commercialization upon U.S. Food and Drug Administration (FDA) approval.
Continue reading on website
Other news

Phase III Study for New TED Drug Demonstrates Positive Effects

June 3, 2026
A 2mm reduction of proptosis is considered to be a clinically meaningful outcome for patients because it is expected to reduce the incidence of diplopia and improve the lid coverage over the cornea and is associated with improvements in quality of life. Photo: Bobby Saenz, OD. Click image to enlarge. Pharmaceutical treatment options for thyroid eye disease (TED) have b

Kits Eyecare Announces Normal Course Issuer Bid, With Nod From Toronto Stock Exchange

June 3, 2026
VANCOUVER, B.C.—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider based in Canada, has announced that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid (NCIB) to purchase a portion of its common shares. Under the NCIB, the company may repurchase up to 1,695,313 shares, according to the announcement, representing 5 perce